TISSUE & FFPE COHORT COLLECTIONS

Renal cell carcinoma tissue microarrays & FFPE blocks

Explore renal cell carcinoma arrays with selected survival and immunotherapy-follow-up records. Check whether pre/post-treatment groups are donor matched. For FFPE blocks, share your tissue and study requirements with our team.

THE ARRAYS

Renal cell carcinoma arrays (14)

Collection types in this TMA catalog

Explore the tissue composition and sampling groups represented in these arrays.

Data labels reflect the catalog record. Review each product and datasheet for case-level coverage. Array counts do not indicate stock availability.

FFPE TISSUE BLOCKS

Renal cell carcinoma FFPE blocks for your study

Renal cell carcinoma with nivolumab follow-up, clinical follow-up, survival or matched plasma.

FFPE blocks are requested by inquiry. Our team confirms tissue availability, donor matching and data coverage for your study.

FFPE TISSUE COHORTS

Renal cell carcinoma FFPE cohorts

Select a cohort or patient profile, then share your sample and data requirements with our team.

Cohort #101

Primary RCC with Nivolumab (IO) treatment follow up information

Cohort #102

Renal Cell Carcinoma (RCC) with follow up data

Cohort #103

Renal Cell Carcinoma (RCC) with survival data

Cohort #182

RCC with matched double spun plasma

Renal cell carcinoma · Patient profile

Stage III/IV or metastatic disease

Renal cell carcinoma · Patient profile

Clear-cell renal cell carcinoma (ccRCC)

Renal cell carcinoma · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

SELECTING YOUR ARRAY

Selecting renal cell carcinoma tissue for your study

Compare the represented tissue and the available records before choosing an array. These examples describe individual catalog entries; data coverage is specific to each array.

TA2880 tissue composition

Renal Cell Carcinoma (RCC) with survival data (TA2880).

TA4345 tissue composition

Primary RCC with Nivolumab (IO) treatment follow up information (TA4345).

TA4445r tissue composition

Renal Cell Carcinoma (RCC) with follow up data.